Circulating EVs for AML minimal residual disease biomarkers detection: PS229
P C Nunes1, H R Caires2, M A Sobrinho-Simões3
1Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal; i3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Portugal; ICBAS-UP - Institute of Biomedical Sciences Abel Salazar of the University of Porto, Portugal.
Porto Biomedical Journal
|April 8, 2020
Abstract
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.5K
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
1.6K
